Join
Live feed
·
PRReleasevia Quantisnow
Jyong Biotech Ltd. logo

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

ByQuantisnow·Wall Street's wire, on your screen.
MENS· Jyong Biotech Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MENS (Jyong Biotech Ltd.) and more on Quantisnow.